Life sciences research and development insights has been saved
Close
Unlocking industry advantage with tech investments
Our new report—drawing on two years of research across six industries—identifies where life sciences and health care industry leaders are directing their technology investments and the tech value signals they use to assess resulting industry advantage.
false
Close
Measuring the return from pharmaceutical innovation 2025
Since 2010, we have been tracking the returns on R&D investment that the largest biopharma companies might expect to achieve from their late-stage pipelines.
false
Close
Algorithm to lab, explore generative AI’s impact in life sciences
Our collection of blogs can be a guidepost in helping strategically adopt generative AI capabilities to amplify value and advance better health outcomes.
false
Close
Broadening research participation through community engagement
Community Health Centers can help increase the diversity and scope of clinical studies—and ultimately, improve patient outcomes.
false
Close
New year, new opportunities: M&A life sciences trends
We’re making five bold 2024 life sciences M&A predictions, which include another strong year for pharma M&A and a positive turn for the MedTech market. Find out what else we expect this year.
false
Close
2024 Life Sciences Industry Accounting Guide
Accounting in life sciences is ever-evolving, with new challenges surfacing and business priorities shifting every day. Deloitte’s 2024 Life Sciences Industry Accounting Guide can help accounting teams address the unique set of issues they face.
false
Close
Impurity regs may affect life sciences pipelines, portfolios
Six steps pharma manufacturers can take to limit nitrosamines and other impurities.
false
Close
Real-world evidence’s evolution into a true end-to-end capability
Find out how biopharmaceutical companies are embedding real-world data and evidence use across the enterprise—and why now is the time.
false
Close
Transforming pharmacovigilance systems
Using technology, analytics, and automation to enable next-gen patient safety; pharmacovigilance (PV) systems are being reshaped by health care trends that include complex global regulations, increasing adverse effect volume, and new sources of data.
false
